retatrutide clinical trial results 2024 2025 press release Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) retatrutide clinical trial results weight

Clinical trials evaluating semaglutide have primarily focused on glycaemic control, cardiovascular outcomes, and weight reduction, with adverse event monitoring centred on gastrointestinal tolerability, hypoglycaemia risk, and complications such as pancreatitis or diabetic retinopathy progression

Regarding gastric emptying, injectable GLP-1RA generally produces a more pronounced and sustained delay, whereas oral semaglutide shows a modest, early-phase effect that attenuates at steady state [74]

What is comparable to Tirzepatide

GLP-1 medications work with your bodys natural systems, ensuring steady, long-term weight loss without drastic side effects

We guide you through testing, evaluation, personalized treatment, and long-term support

doi: 10.1001/jamainternmed.2022.0335 [DOI] [PubMed] [Google Scholar] 20